PROJECT SUMMARY This administrative supplement is to continue the ongoing support of the PNNL lead Omics Data Generation Center (PNNL-ODGC) within the broader context of the A2CPS consortium. Delays within the A2CPS consortium primarily due to recruitment in the MCC1 and MCC2 clinical site components have facilitated the extension of efforts beyond the planned timeframe of the A2CPS consortium. Though extensive carry-over funds have been secured and will be used to extend the analysis timeframe of the PNNL-ODGC efforts, there still remain gaps in funding based upon current expected recruitment goals, timeframes, and the subsequent proteomic sample analysis needs. Overall, the objective of the PNNL-ODGC remains, which is to develop and implement high throughput proteomics-based assays for quantifying a broad and diverse set of molecular players associated with acute to chronic pain conversion with the goal to develop predictive signatures as well as inform upon relevant molecular mechanisms. This brings together advanced mass spectrometry (MS) proteomics capabilities (Pacific Northwest National Laboratory, PNNL) and high throughput screening capabilities (Luminex Core at University of Pittsburgh Medical Center, UPMC) to accurately detect and quantify a broad spectrum of primary and secondary marker targets as well as provide a robust proteomic discovery element for further investigation.